Abstract
Objective: Identify the main antiemetic drugs related to pediatric oncology and propose, through pharmaceutical assistance, strategies for the best therapy during chemotherapy treatment, ensuring the protection and recovery of patients. Methods: Integrative review, with no restrictions on the design or language of the study, selecting publications from the last 5 years, which included only children aged 0 to under 18 years undergoing chemotherapy. Results: There are several drug classes applicable, reaching the following therapies: High emetic risk: serotonin antagonists (Granisetron, Ondansetron or Palonosetron), Dexamethasone and Aprepitant. Moderate: Serotonin antagonist and Dexamethasone. Low: serotonin antagonist. Some of these drugs have a large financial impact, as they are not part of the standardization of the Unified Health System. Final considerations: The construction of this integrative review, the importance of the addressed theme is observed, being in the focus of reference centers in Europe and North America, which recommend the use of antiemetics through protocols, using safe drug classes for this age group. However, there are still few studies outside these reference centers, such as in Brazil and Latin America, where no studies were found. Therefore, it is important to bring and apply this information in our reality, aiming to improve the care provided to the patient.